CELLINK collaborator from MIT together with the leading research institutions Harvard, ETH Zurich, Utrecht and Eindhoven University of Technology have 3D-Bioprinted a model of human heart valve disease models.
For this study, the CELLINK INKREDIBLE+ was used to bioprint the model of the human heart valve.
They measured the mechanical properties of the individual layers of diseased aortic valves and replicated those properties in a 3D-Bioprinted model. By printing human aortic valve cells inside this model, they can recreate aortic valve calcification in the lab to research the mechanisms and test different types of medication against this disease. Read the full publication: http://www.mdpi.com/2079-4991/8/5/296/htm
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: +46 73 267 00 00 Phone: +46 70 991 86 04
CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK and Mangold Fondkommission AB, tel: +46 (0) 8 5030 1550, is the Company's Certified Adviser.